An inverse agonist of orphan receptor GPR61 acts by a G protein-competitive allosteric mechanism

  • Nat Commun. 2023 Sep 23;14(1):5938. doi: 10.1038/s41467-023-41646-3.
Joshua A Lees  #  1 João M Dias  #  1 Francis Rajamohan  1 Jean-Philippe Fortin  2 Rebecca O'Connor  1 Jimmy X Kong  2 Emily A G Hughes  2 Ethan L Fisher  3 Jamison B Tuttle  4 Gabrielle Lovett  4 Bethany L Kormos  4 Rayomand J Unwalla  4 Lei Zhang  4 Anne-Marie Dechert Schmitt  3 Dahui Zhou  3 Michael Moran  3 Kimberly A Stevens  2 Kimberly F Fennell  1 Alison E Varghese  1 Andrew Maxwell  1 Emmaline E Cote  1 Yuan Zhang  4 Seungil Han  5
Affiliations
  • 1. Discovery Sciences, Medicine Design, Pfizer Inc., Groton, CT, USA.
  • 2. Internal Medicine Research Unit, Pfizer Inc., Cambridge, MA, USA.
  • 3. Internal Medicine, Medicine Design, Pfizer Inc., Groton, CT, USA.
  • 4. Internal Medicine, Medicine Design, Pfizer Inc., Cambridge, MA, USA.
  • 5. Discovery Sciences, Medicine Design, Pfizer Inc., Groton, CT, USA. [email protected].
  • # Contributed equally.
Abstract

GPR61 is an orphan GPCR related to biogenic amine receptors. Its association with phenotypes relating to appetite makes it of interest as a druggable target to treat disorders of metabolism and body weight, such as obesity and cachexia. To date, the lack of structural information or a known biological ligand or tool compound has hindered comprehensive efforts to study GPR61 structure and function. Here, we report a structural characterization of GPR61, in both its active-like complex with heterotrimeric G protein and in its inactive state. Moreover, we report the discovery of a potent and selective small-molecule inverse agonist against GPR61 and structural elucidation of its allosteric binding site and mode of action. These findings offer mechanistic insights into an orphan GPCR while providing both a structural framework and tool compound to support further studies of GPR61 function and modulation.

Products